Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 15/20 | 0.53 |
| ▸ | PDE4A | P27815 | 14/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6607854 | 1.00 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DLMNA | |
| SCHEMBL29357646 | 1.00 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DLMNA | |
| SCHEMBL4958570 | 1.00 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DLMNA | |
| SCHEMBL4957740 | 0.96 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DLMNA | |
| SCHEMBL7654261 | 0.96 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DLMNA | |
| SCHEMBL7654256 | 0.96 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DLMNA | |
| SCHEMBL7659290 | 0.93 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DLMNA | |
| SCHEMBL7659295 | 0.93 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DLMNA | |
| SCHEMBL7659299 | 0.93 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DLMNA | |
| SCHEMBL6602217 | 0.90 | KDM4E (0.42) | PDE4BPDE4APDE4CPDE4DLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230009902-A1 | TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORGINATING FROM THE ENDODERM | GLAS USA LLC | 2023-01-12 | — | — | US | disclosed |
| US-20210031012-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A PDE4 INHIBITOR | GLAS USA LLC | 2021-02-04 | — | — | US | disclosed |
| US-20200323772-A1 | TREATMENT OF INFLAMMATORY DISEASE USING INGESTIBLE DEVICE TO RELEASE IMMUNE MODULATOR | BT BIDCO LLC | 2020-10-15 | — | — | US | disclosed |
| WO-2019246317-A9 | TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORIGINATING FROM THE ENDODERM | PROGENITY, INC. (US) | 2020-07-16 | — | — | WO | disclosed |
| WO-2019147824-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A PDE4 INHIBITOR | PROGENITY, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
| WO-2019036382-A1 | TREATMENT OF INFLAMMATORY DISEASE USING INGESTIBLE DEVICE TO RELEASE IMMUNE MODULATOR | PROGENITY INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| US-20080085858-A1 | Pharmaceutical Composition | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-04-10 | — | — | US | disclosed |
| US-20080085858-A1 | Pharmaceutical Composition | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2008-04-10 | — | — | US | disclosed |
| US-20070287689-A1 | Therapeutic And/Or Preventive Agents For Chronic Skin Diseases | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-12-13 | — | — | US | disclosed |
| US-20070287689-A1 | Therapeutic And/Or Preventive Agents For Chronic Skin Diseases | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-12-13 | — | — | US | disclosed |
| EP-1813284-A1 | PHARMACEUTICAL COMPOSITION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
| EP-1810692-A1 | REMEDIES/PREVENTIVES FOR CHRONIC SKIN DISEASE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-07-25 | — | — | EP | disclosed |
| EP-1110961-B1 | OXYGENIC HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO KK (JP) | 2004-07-14 | — | — | EP | disclosed |
| US-20040054197-A1 | Styrene derivatives and process for production thereof | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1362853-A1 | STYRENE DERIVATIVES AND PROCESS FOR PRODUCTION THEREOF | Kyowa Hakko Kogyo Co., Ltd (JP) | 2003-11-19 | — | — | EP | disclosed |
| US-6376535-B2 | PHOSPHODIESTERASE (PDE) INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-04-23 | — | — | US | disclosed |
| US-20010056117-A1 | Oxygen-containing heterocyclic compounds | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2001-12-27 | — | — | US | disclosed |
| EP-1110961-A1 | OXYGENIC HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-06-27 | — | — | EP | disclosed |
| JP-2000319166-A | ENTERIC PREPARATION | KYOWA HAKKO KOGYO CO LTD | 2000-11-21 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210031012-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A PDE4 INHIBITOR | PDE4A, PDE12, PDE4B | PDE4B 3/4885PDE4A 1/4885PDE4C 4/4885 |
| US-20010056117-A1 | Oxygen-containing heterocyclic compounds | CBR1, CBR3, MT-CO1 | PDE4B 2596/4885PDE4A 2844/4885PDE4C 3154/4885 |
| US-20080085858-A1 | Pharmaceutical Composition | PDE3B, PDE3A, PDE5A | PDE4B 5/4885PDE4A 4/4885PDE4C 6/4885 |
| US-20040054197-A1 | Styrene derivatives and process for production thereof | HSD3B1, SULT1A1, HSD3B2 | PDE4B 4492/4885PDE4A 4611/4885PDE4C 4823/4885 |
| US-20230009902-A1 | TREATMENT OF A DISEASE OR CONDITION IN A TISSUE ORGINATING FROM THE ENDODERM | ALPG, ALPP, FABP2 | PDE4B 1544/4885PDE4A 1695/4885PDE4C 1968/4885 |
| US-20200323772-A1 | TREATMENT OF INFLAMMATORY DISEASE USING INGESTIBLE DEVICE TO RELEASE IMMUNE MODULATOR | LRBA, CD47, FABP2 | PDE4B 611/4885PDE4A 559/4885PDE4C 874/4885 |
| US-20070287689-A1 | Therapeutic And/Or Preventive Agents For Chronic Skin Diseases | PDE4A, PDE3B, PDE2A | PDE4B 7/4885PDE4A 1/4885PDE4C 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.